Skip to main content
Premium Trial:

Request an Annual Quote

Paradigm Genetics Reports Q2 Revenues Growth

NEW YORK, Aug 2 (GenomeWeb News) - Paradigm Genetics posted on Monday a second-quarter net loss essentially flat with the year-ago quarter, despite a 12 percent rise in revenues during the period.


Paradigm's revenues in the quarter were $6.3 million, up from $5.6 million in the second quarter 2003.


Meanwhile, the company's research and development spending climbed to $6.8 million in the second quarter, compared with $6.5 million in the year-ago period, helping to drive overall expenses about $800,000 higher to $9.8 million.


Paradigm reported a second-quarter net loss of $3.6 million. As of June 30, the company had cash, cash equivalents, and short-term investments totaling about $10.7 million.


The Scan

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.

Sequencing Study Leads to Vaccine Target in Bacteria Behind Neonatal Meningitis

Researchers eBioMedicine track down potential vaccine targets with transposon sequencing on mutant bacteria causing neonatal meningitis in mouse models of the disease.

Multiple Myeloma Progression Influenced by Immune Microenvironment Expression

Researchers in NPJ Genomic Medicine compare RNA sequencing profiles of 102,207 individual cells in bone marrow samples from 18 individuals with rapid or non-progressing multiple myeloma.

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.